

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-16. (Canceled)

17. (Currently Amended) A method for treating chronic lymphocytic leukemia (CLL) in a mammalian subject comprising administering to said subject an effective amount of an isolated monoclonal antibody that specifically binds to a polypeptide comprising the sequence set forth in SEQ ID NO: 4 ~~wherein said monoclonal antibody has a binding constant for SEQ ID NO:4 that exceeds 10³L/mol, and does not react detectably with polypeptides unrelated to SEQ ID NO:4.~~

18-20. (Canceled)

21. (Previously Presented) The method of claim 17, wherein said antibody is a humanized antibody.

22. (Previously Presented) The method of claim 17, wherein said antibody is a chimeric antibody.

23. (Previously Presented) The method of claim 17, wherein said antibody is a Fab fragment.

24. (Currently Amended) The method of claim 17, wherein said antibody is a Fv fragment ~~fragment~~.

25. (Previously Presented) The method of claim 17, wherein said antibody is a scFv.

26. (Previously Presented) The method of claim 17, wherein said antibody further comprises a therapeutic moiety.

27. (Previously Presented) The method of claim 26, wherein the therapeutic moiety is a radionuclide.

28. (Previously Presented) The method of claim 27, wherein the radionuclide is a member selected from the group consisting of: ^{90}Y , ^{123}I , ^{125}I , ^{131}I , ^{186}Re , ^{211}At , and ^{212}Bi .

29-31. (Canceled)

32. (Previously Presented) The method of claim 27, wherein the mammalian subject is a human.

33. (Previously Presented) The method of claim 17, wherein administration is intravenous.

34-53. (Canceled)

54. (Previously Presented) The method of claim 17, wherein the monoclonal antibody is not a bi-specific antibody.